CompletedNot Applicable

Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia

Belgium66 participantsStarted 2009-03

Plain-language summary

The aim of the trial was to assess whether use of the TEGO connector was able to reduce the incidence of a composite endpoint of TCC-related dysfunction (TCC-D)or TCC-related bacteremia (TCC-B) in chronic hemodialysis (HD) patients carrying the TEGO® connector vs controls receiving trisodium citrate 46.7%.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult HD patients, prevalent or incident,carrying a tunneled cuffed catheter * Tunneled cuffed catheter providing a mean blood flow superior to 250 ml/min * Patients having signed an informed consent Exclusion Criteria: * Mature arterio-venous fistula * Episode of TCC-related bacteremia 1 week before randomization

What they're measuring

Incidence rate of tunneled cuffed catheter-related dysfunction or bacteremia (composite endpoint)

Timeframe: 16 months

Trial details

NCT IDNCT01689753

SponsorErasme University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-04

View on ClinicalTrials.gov More Other Complication of Vascular Dialysis Catheter trials